Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-4: Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in ER+, HER2- Early Breast Cancer
jRCT2031230109Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imlunestrant in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Invasive Disease-Free Survival (IDFS). Started Dec 2022; status: active, not recruiting.
02
Drugs
imlunestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031230109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230109.